Evidence map›Paper›PMID 41582224›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2026

CTLA-4 haploinsufficiency presenting with chronic myeloid leukemia, bullous pemphigoid, and PLA2R-positive membranous nephropathy: a case report.

Nouraldeen Deeb, Salahaldeen Deeb, Fares Sayed Ahmed, Younis Malik Younis Amro, Abdallah Altell, Aliaa Khalili

Abstract read
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nouraldeen DeebFaculty of Medicine, Al-Quds University, East Jerusalem, Occupied Palestinian Territory. Nourdeeb2011@gmail.com.
Salahaldeen DeebFaculty of Medicine, Al-Quds University, East Jerusalem, Occupied Palestinian Territory.
Fares Sayed AhmedFaculty of Medicine, Al-Quds University, East Jerusalem, Occupied Palestinian Territory.
Younis Malik Younis AmroFaculty of Medicine, Al-Quds University, East Jerusalem, Occupied Palestinian Territory.
Abdallah AltellFaculty of Medicine, Al-Quds University, East Jerusalem, Occupied Palestinian Territory.
Aliaa KhaliliFaculty of Medicine, Al-Quds University, East Jerusalem, Occupied Palestinian Territory. Aliaa.khalili@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytotoxic T-lymphocyte–associated protein 4 (CTLA-4) haploinsufficiency is a primary immune-regulatory disorder characterized by T-cell overactivation and multisystem autoimmunity. Malignancies, particularly lymphomas and gastric cancer, have been reported in approximately 12–13% of individuals with CTLA-4 haploinsufficiency, but associations with chronic myeloid leukemia (CML) are very rarely described. We report a young adult with genetically and functionally confirmed CTLA-4 haploinsufficiency who developed a triad of BCR-ABL1–positive chronic myeloid leukemia (CML), bullous pemphigoid, and PLA2R-positive membranous glomerulonephritis (MGN), highlighting diagnostic and management lessons across immunology, hematology, dermatology, and nephrology. CASE PRESENTATION: A 21-year-old woman with Hashimoto thyroiditis and iron-deficiency anemia was found to have BCR-ABL1–positive CML. Within months she developed recurrent infections and paraneoplastic blistering disease. Whole-exome sequencing detected a heterozygous CTLA4 c.529_530insT (p.Tyr177LeufsTer2) frameshift; flow cytometry showed reduced CTLA-4 expression, establishing functional haploinsufficiency. Six months later she presented with edema and nephrotic-range proteinuria; serology revealed markedly elevated anti-PLA2R antibodies, and kidney biopsy confirmed immune-complex MGN. Management included a TKI (imatinib/nilotinib as indicated over the course), low-dose corticosteroids, monthly IVIG for infection/immune modulation, and rituximab for bullous disease and MGN. This resulted in molecular remission of CML, resolution of skin lesions, and sustained normalization of proteinuria over 12 months.

conclusionsThe convergence of CML, bullous pemphigoid, and PLA2R-positive MGN in CTLA-4 haploinsufficiency broadens the clinical phenotype and underscores the importance of considering inborn errors of immunity in young adults with refractory, multisystem autoimmunity and hematologic abnormalities. Early genetic diagnosis can guide targeted immunomodulation and organ preservation, and multidisciplinary care is essential for optimal outcomes.

Indexed as

Case reportChronic myeloid leukemia (CML)CTLA-4 haploinsufficiencyMembranous glomerulonephritis (MGN)Paraneoplastic syndromes

Identifiers

PMID41582224
PMCPMC12879419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.